Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
2000 1
2002 1
2004 1
2005 9
2006 29
2007 33
2008 44
2009 77
2010 115
2011 227
2012 268
2013 253
2014 286
2015 309
2016 336
2017 398
2018 408
2019 428
2020 507
2021 533
2022 526
2023 511
2024 503
2025 34

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,124 results

Results by year

Filters applied: . Clear all
Page 1
Denosumab Discontinuation.
Sølling AS, Tsourdi E, Harsløf T, Langdahl BL. Sølling AS, et al. Curr Osteoporos Rep. 2023 Feb;21(1):95-103. doi: 10.1007/s11914-022-00771-6. Epub 2022 Dec 24. Curr Osteoporos Rep. 2023. PMID: 36564572 Review.
PURPOSE OF REVIEW: To review the pathophysiology, the clinical consequences as well as way of mitigating the effects of denosumab discontinuation. RECENT FINDINGS: Treatment with denosumab (DMAB) is reversible and upon discontinuation there is a rapid increase in bo …
PURPOSE OF REVIEW: To review the pathophysiology, the clinical consequences as well as way of mitigating the effects of denosumab dis …
Denosumab in elderly osteoporotic patients. A narrative review.
Di Lorenzo L. Di Lorenzo L. Clin Ter. 2023 Nov-Dec;174(6):545-549. doi: 10.7417/CT.2023.5023. Clin Ter. 2023. PMID: 38048119 Free article. Review.
OBJECTIVE: Denosumab, an antiresorptive agent, has shown results in improving bone mineral density and reducing fractures in postmenopausal women. ...This narrative literature review aimed to assess the use of denosumab in elderly individuals with osteoporosis, excl …
OBJECTIVE: Denosumab, an antiresorptive agent, has shown results in improving bone mineral density and reducing fractures in postmeno …
Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y. Kobayakawa T, et al. Sci Rep. 2021 Jun 3;11(1):11801. doi: 10.1038/s41598-021-91248-6. Sci Rep. 2021. PMID: 34083636 Free PMC article.
Sixty-nine patients each received either denosumab or romosozumab for 12 months. The mean 12-month percentage change from baseline in lumbar spine BMD was 7.2% in the denosumab group and 12.5% in the romosozumab group, indicating a significant difference between the …
Sixty-nine patients each received either denosumab or romosozumab for 12 months. The mean 12-month percentage change from baseline in …
Stopping Denosumab.
Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG. Lamy O, et al. Curr Osteoporos Rep. 2019 Feb;17(1):8-15. doi: 10.1007/s11914-019-00502-4. Curr Osteoporos Rep. 2019. PMID: 30659428 Review.
In five recent case series, the median number of vertebral fractures was 5 within 7 to 20 months (median 11) after the last denosumab injection. Prescribing bisphosphonate before starting denosumab and/or after stopping denosumab may reduce this risk. ...A po …
In five recent case series, the median number of vertebral fractures was 5 within 7 to 20 months (median 11) after the last denosumab …
Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.
Shane E, Shiau S, Recker RR, Lappe JM, Agarwal S, Kamanda-Kosseh M, Bucovsky M, Stubby J, Cohen A. Shane E, et al. J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1528-e1540. doi: 10.1210/clinem/dgab850. J Clin Endocrinol Metab. 2022. PMID: 34849989 Free PMC article. Clinical Trial.

Over the entire 24-month teriparatide and 24-month denosumab treatment period, BMD increased by 21.9 7.8% at the LS, 9.8 4.6% at the TH, and 9.5 4.7% at the FN (all P < .0001). ...Serum BTM decreased by 75% to 85% by 3 months and remained suppressed through 12 months of

…
Over the entire 24-month teriparatide and 24-month denosumab treatment period, BMD increased by 21.9 7.8% at the LS, 9.8 4.6% at the …
Differences between zoledronic acid and denosumab for breast cancer treatment.
Ishikawa T. Ishikawa T. J Bone Miner Metab. 2023 May;41(3):301-306. doi: 10.1007/s00774-023-01408-z. Epub 2023 Mar 7. J Bone Miner Metab. 2023. PMID: 36879056 Review.
Zoledronic acid and denosumab are bone-modifying agents that are clinically important in multiple aspects of bone management for breast cancer patients. ...It provides significant benefits for improving breast cancer mortality in patients with suppressed estrogen level suc …
Zoledronic acid and denosumab are bone-modifying agents that are clinically important in multiple aspects of bone management for brea …
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, Matsumoto T, Milmont CE, Libanati C, Grauer A. Cosman F, et al. J Bone Miner Res. 2018 Jul;33(7):1219-1226. doi: 10.1002/jbmr.3427. Epub 2018 May 17. J Bone Miner Res. 2018. PMID: 29573473 Free article. Clinical Trial.
Here, we further characterize the BMD gains with romosozumab by quantifying the percentages of patients who responded at varying magnitudes; report the mean T-score changes from baseline over the 2-year study and contrast these results with the long-term BMD gains seen with de …
Here, we further characterize the BMD gains with romosozumab by quantifying the percentages of patients who responded at varying magnitudes; …
Safety and Efficacy of Denosumab for Fibrous Dysplasia of Bone.
de Castro LF, Michel Z, Pan K, Taylor J, Szymczuk V, Paravastu S, Saboury B, Papadakis GZ, Li X, Milligan K, Boyce B, Paul SM, Collins MT, Boyce AM. de Castro LF, et al. N Engl J Med. 2023 Feb 23;388(8):766-768. doi: 10.1056/NEJMc2214862. N Engl J Med. 2023. PMID: 36812441 Free PMC article. No abstract available.
Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.
Kobayashi T, Morimoto T, Ito K, Mawatari M, Shimazaki T. Kobayashi T, et al. Osteoporos Int. 2024 Aug;35(8):1377-1393. doi: 10.1007/s00198-024-07118-0. Epub 2024 May 11. Osteoporos Int. 2024. PMID: 38733394 Review.
Denosumab and bisphosphonates for primary osteoporosis are generally well-tolerated, but their comparative safety remains unclear. ...We explored the comparative safety of denosumab and bisphosphonates for primary osteoporosis, some of which could be attributed to t …
Denosumab and bisphosphonates for primary osteoporosis are generally well-tolerated, but their comparative safety remains unclear. .. …
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A. McClung MR, et al. J Bone Miner Res. 2018 Aug;33(8):1397-1406. doi: 10.1002/jbmr.3452. Epub 2018 May 22. J Bone Miner Res. 2018. PMID: 29694685 Free article. Clinical Trial.
Women receiving romosozumab who transitioned to denosumab continued to accrue BMD, whereas BMD returned toward pretreatment levels with placebo. ...These data suggest that treatment effects of romosozumab are reversible upon discontinuation and further augmented by deno …
Women receiving romosozumab who transitioned to denosumab continued to accrue BMD, whereas BMD returned toward pretreatment levels wi …
5,124 results